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Bei Menschen mit chronischer Herzinsuffizienz ist Eisenmangel eine häufige Komorbidität. 
Eine intravenöse Eisentherapie verbessert signifikant Belastbarkeit und Lebensqualität dieser 
Patienten. Die Richtlinien der European Society of Cardiology empfehlen deshalb, bei 
symptomatischen Herzpatienten mit reduzierter Ejektionsfraktion und Eisenmangel eine 
intravenöse Eisencarboxymaltose-Therapie in Betracht zu ziehen. Die vorliegende Studie 
untersuchte, ob bei Hunden in unterschiedlichen Stadien einer Mitralendokardiose (ME) 
ebenfalls ein vergleichbarer Eisenmangel als Komorbidität vorliegt. 
Bei privaten Hunden mit einer ME wurden Hämatologie, Chemogramm und Eisenstatus, d.h. 
Serum-Eisen, Transferrinsättigung (Tsat), Ferritin und Gesamteisenbindungskapazität 
durchgeführt. Eingeschlossen wurden Hunde in den Stadien B2 (n= 33) und C (n= 37), 
gemäss ACVIM Konsensus Klassifikation. Als Kontrolle dienten 30 gesunde Hunde. 
Hämatologisch unterschieden sich die Gruppen nicht. Das Serum-Eisen war bei C-Hunden 
signifikant niedriger als bei B2-Hunden (p = 0,03) und den Kontrollhunden (p = 0,016) und 
korrelierte negativ mit der Grösse der linken Ventrikel (r = -0,23); Tsat war bei C-Hunden 
signifikant niedriger als bei B2-Hunden (p = 0,031).  
Wird Eisenmangel als erniedrigtes Serum-Eisen oder eine Tsat <20% definiert, wiesen zwei 
B2-Hunde und sieben C-Hunde einen Eisenmangel auf. Diese Daten implizieren, dass eine 
Untergruppe von Hunden mit fortgeschrittener ME an einem Eisenmangel leiden.  
 






In humans with chronic heart failure, iron deficiency is a common comorbidity and 
intravenous iron therapy significantly improves exercise capacity and quality of life. The 
European Society of Cardiology Guidelines recommend considering intravenous ferric 
carboxymaltose therapy in symptomatic patients with heart failure with reduced ejection 
fraction and iron deficiency. 
The objective of this study was to assess if iron deficiency is a comparable comorbidity in 
dogs at various stages of myxomatous mitral valve disease (MMVD). Hematology,  
biochemical analysis and iron status, i.e., serum iron, ferritin, transferrin saturation (Tsat) and 
total iron-binding capacity, were obtained in client-owned dogs with MMVD, in stage B2 
(n=33) and C (n=37) heart failure, according to the ACVIM Consensus Classification. A 
control group of 30 healthy dogs was used as a comparison.  
Hematological parameters were consistent between the groups. Serum iron was significantly 
lower in stage C compared to stage B2 (p = 0.03) and control dogs (p=0.016) and negatively 
correlated with left ventricular size (r = -0.23); Tsat was significantly lower in stage C 
compared to B2 dogs (p = 0.031). When using decreased serum iron or Tsat <20% as 
diagnostic criteria, two in stage B2 and seven in stage C were iron deficient. These data 
suggest presence of iron deficiency in a subset of dogs with advanced MMVD.  
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Introduction  
Chronic heart failure (CHF) in dogs is a medical condition most commonly seen as the 
consequence of mitral regurgitation in myxomatous mitral valve disease (MMVD) 
(Buchanan, 1999; Kvart and Häggström, 2000; Baumgartner and Glaus, 2004). In human 
medicine, chronic heart failure CHF is a clinical problem of utmost importance with around 
26 million people affected worldwide (Ponikowski et al., 2014a). Therefore, this condition is 
a medical and economic issue with epidemic qualities (Bui et al., 2011). Besides reduced life 
expectancy in humans (Cowie et al, 2000), impaired quality of life (QoL) is widely discussed 
(Hoekstra et al., 2011). Among other factors, iron deficiency (ID) is a proven and common 
comorbidity responsible for reduced QoL in humans, having a negative impact on the clinical 
situation and prognosis (Ponikowski et al., 2014b). Treatment of ID with intravenous ferric 
carboxymaltose (FCM) has been shown to significantly improve QoL and the New York 
Heart Association (NYHA) class (Anker et al., 2009). A follow-up trial further revealed that 
intravenous iron therapy had a positive impact on exercise capacity and reduced the risk of 
hospitalizations (Ponikowski et al., 2015). As a consequence of these findings, the 2016 
guidelines of the European Society of Cardiology recommend screening symptomatic 
patients with heart failure with reduced ejection fraction for ID and, if present, considering 
treatment with FCM (Ponikowski et al., 2016). In humans, ID has been defined as serum 
ferritin <100 µg/L, or ferritin between 100–299 µg/L and transferrin saturation (Tsat) <20% 
(Ponikowski et al., 2016). Recently, this definition has been questioned and the diagnostic 
value of Tsat and serum iron to diagnose ID reconsidered (Grote Beverborg et al., 2018). In 
this study, Tsat <20% or low serum iron showed the best performance for detecting ID and 
best identified heart failure patients at the highest risk of death. Furthermore, Tsat and serum 
iron, but not ferritin, were independently 
associated with mortality, which brings into question the diagnostic value of ferritin in the 
scenario of CHF (Grote Beverborg et al., 2018).  
 
   
6 
In dogs with CHF, the situation may be comparable; however, before translating treatment 
recommendations from human to veterinary cardiology, it should be confirmed that dogs 
diagnosed with CHF are similarly suffering from ID. Therefore, this study aimed to 
investigate whether, and to what extent, ID is a comorbidity in dogs suffering from CHF. We 
hypothesized that ID is common in dogs with MMVD and that the severity would increase as 
the disease progresses. 
 
Materials and Methods 
The objective of this multicenter, prospective case-controlled study was to test the hypothesis 
that dogs with CHF due to MMVD suffer from iron deficiency. The primary endpoint was 
iron status, the secondary endpoint was presence of anemia. Four centers participated in the 
study, the Divisions of Cardiology Vetsuisse Faculty Universities of Zurich and Bern, 
Department of Veterinary Medical Sciences University of Bologna, and Bessy’s 
Kleintierklinik, CH-Watt. The study was approved by the State Veterinary Office of Zurich 
(Application number ZH 261/16). 
 
Animals 
Dogs were prospectively enrolled into the study from patients having cardiological 
examination for medical concerns, such as preventive cardiac checkup, pre-anesthesia 
assessment, heart murmur, weakness, exercise intolerance, syncope, cough, or dyspnea. 
Owners were thoroughly informed about the study via written statement and a client consent 
form was signed. All dogs underwent complete clinical and echocardiographic examination. 
In dogs with respiratory signs, thoracic radiographs in two perpendicular projections were 
performed to check presence of pulmonary infiltrates compatible with lung edema. Dogs with 
an echocardiographic diagnosis of MMVD were enrolled if they had cardiomegaly defined as 
left ventricular internal diameter at end diastole normalized to body weight (LVDDN) >1.7. 
They were classified as compensated (stage B2) or decompensated (stage C) in accordance 
with the ACVIM classification guidelines (Atkins et al., 2009). Systemic blood pressure 
measurement was carried out using an oscillometric method in each dog following published 
guidelines (Brown et al., 2007). Predefined exclusion criteria were any disease in addition to 
MMVD and any treatment in the previous four weeks besides cardiac drugs or routine 
antiparasitic drugs. 
As controls, healthy dogs, based on history, physical and echocardiographic examination, 
were recruited from dogs attending for preventive cardiac checkup or pre-anesthesia 
assessment, and dogs owned by staff and students. These dogs were presented in the same 
period and similarly prospectively enrolled. The owners were thoroughly informed and 
signed a client consent form.  
 
Echocardiography 
Complete echocardiographic exams were performed with an Epiq 7 (Philips Medical, TG and 
MBT) or a Vivid 7 (GE Medical Systems, AK and IV) Ultrasound System in right and left 
lateral recumbency using standard views (Thomas et al., 1993). The diagnosis of MMVD was 
based on visible degenerative changes on two-dimensional (2-D) echocardiography and 
mitral valve insufficiency on color doppler examination (Boswood et al., 2016). The left 
ventricular internal diameter was measured from a 2-D guided M-Mode image obtained from 
a right parasternal short-axis view at the level of the papillary muscles (Boswood et al., 
2016). The left atrial to aortic root ratio (LA/Ao) was also obtained from a short-axis view 
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Laboratory analyses 
In order to evaluate the iron status, the following iron specific and ID-related parameters 
were analyzed: serum iron, Tsat, total iron binding capacity (TIBC), ferritin, hemoglobin 
(Hb), erythrocyte indices and the reticulocyte hemoglobin equivalent (RET-He). Four ml of 
blood was drawn either from the jugular or cephalic vein with caution to prevent hemolysis. 
Serum for analysis of iron specific parameters was immediately frozen and kept at -80° C; 
serum was carried on dry ice to the Laboratory at University of Bologna, where it was 
analyzed in batches. Serum iron and TIBC were measured using colorimetric methods (Iron 
Ferene, KAL 002, Olympus /Sentinel; UIBC OSR61205, Olympus/Beckman Coulter). Serum 
ferritin was measured using an assay validated for dogs (Ferritin OSR 61203, 
Olympus/Beckman Coulter) after standard internal validation. 
To identify non-cardiogenic factors, e.g. inflammatory conditions, that might affect iron 
parameters like ferritin (Bohn, 2013; Grote Beverborg et al., 2018), a complete blood count, 
routine biochemical profile and serum C-reactive protein (CRP) were obtained. 
Hematological analyses were performed on an automated hematology analyzer (Sysmex-XT 
2000iv). Biochemical analyses were performed on fully automated chemistry analyzers 
(Vetsuisse Zurich, Berne and Bessy’s, Cobas 6000 c 501, Roche; Bologna, Olympus AU 480, 
Olympus/Beckman Coulter). C-reactive protein was measured using an immunoturbidimetric 
assay (CRP OSR6147, Olympus/Beckman Coulter).  
 
Statistical methods 
Data processing and statistical evaluation were performed with R (v3.5, R Core Team 2013). 
The normal distribution of measurement errors was ascertained through visual inspection 
using QQ-plots from the Car Package (v.3.0.2, Fox & Weisberg, 2019) and by inspecting the 
standardized residuals. All data were normally distributed. Therefore, analysis of variance 
was performed to test effect of disease stage on performed measurements. For significant 
differences, subsequent pairwise comparisons of group means were performed using Tukey’s 
Range Test with the Agricolae Package (v1.3.0, https://CRAN.R-
project.org/package=agricolae). 
Pairwise monotonic relationships between measurements were calculated with Spearman 
correlation, using the Hmisc Package (v.4.1.1, https://CRAN.R-project.org/package=Hmisc) 
and significance was set at P <0.05.  
 
Results 
Seventy dogs with CHF and 30 control dogs were included. Of the dogs with CHF, 33 (47%) 
were classified as stage B2, 37 (53%) as stage C. Control dogs were younger than dogs with 
CHF and body condition score was significantly lower in stage C dogs compared to both 
control and stage B2 dogs (table 1). There was a large variety of breeds in each class with 
only Chihuahua (n= 12), Cavalier King Charles (n= 8) and Jack Russel Terrier (n=6) 
appearing more than twice in total. The LVDDN and LA/Ao values were, by definition, 
smaller in control dogs than those with heart disease, and significantly larger in stage C 
compared to stage B2 dogs (p <0.01, table 1). 
The laboratory parameters and correlations are summarized in tables 2-4. The hematological 
parameters were consistent between the groups, even though hemoglobin concentration 
correlated with each parameter of iron status. No significant differences in RET-He were 
identified between the groups. The CRP concentration was significantly higher in stage C 
compared to stage B2 and control dogs (P <0.01). 
Serum iron was significantly lower in stage C dogs (118 + 56 ug/dl) compared to control 
(156 + 45 ug/dl, p = 0.016) and stage B2 (151 + 57 ug/dl, p= 0.030) dogs (figure 1, table 3). 
Tsat was significantly lower in stage C dogs (30 + 12%) compared to control dogs (39 + 
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12%, p = 0.031), but not compared to stage B2 (37 + 14%, p = 0.078) dogs (figure 2). There 
were no differences in TIBC and ferritin between the groups.  
Seven dogs had a serum iron concentration below the reference range; Tsat was <30% in all 
seven and <20% in six of these. One of these seven dogs was in class B2 (LVDDN 2.4); the 
other six were in class C (LVDDN 2.1-2.6). Five of these seven dogs had an elevated CRP of 
17-193 mg/l. An additional two dogs had a Tsat below 20%; one of these was in stage B2 
(LVDDN 2.0) with a TSAT of 18%, serum iron of 58 ug/ml and low CRP <10 mg/l; the other 
was in stage C (LVDDN 2.3) with a TSAT of 19%, serum iron of 90 ug/dl and CRP <10 
mg/l. An additional 26 dogs had a TSAT <30%, eight of these were control dogs, and nine 
each in stage B2 and C. In these, the CRP was elevated in five stage C dogs, one stage B2 
dog and two control dogs.     
The following correlations were found: The serum iron weakly and negatively correlated 
with LVDDN (r = -0.23, P = 0.03), body condition score (r = -0.35, P = <0.01) and CRP (r = 
-0.28, p < 0.01). The CRP also weakly and negatively correlated with Tsat (r = -0.27, P = 
0.01) and body condition score (r = -0.3, P = 0.01), and it weakly correlated with LVDDN (r 
= 0.21, P = 0.05) and LA/Ao (r = 0.22, P = 0.05). The body condition score also negatively 
correlated with LVDDN (r = -0.39, P <0.01) and LA/Ao (r = -0.45, P = <0.01). 
 
Discussion 
In human patients with CHF, ID - with or without associated anemia - is an important 
comorbidity which receives therapeutic attention. Our study failed to provide any evidence 
for anemia in dogs even with advanced MMVD. Furthermore, if ID is diagnosed based on 
serum ferritin, this study also failed to identify ID without anemia. However, several dogs 
had low serum iron concentration; all in stage C heart failure with one exception, indicating 
ID could be a potential comorbidity of CHF in dogs. If the criteria for diagnosing ID in 
veterinary hematology (Naigamwalla et al., 2012), or recently suggested in human cardiology 
(Grote Beverborg et al., 2018) are applied; low serum iron or Tsat <20%, ID was present in 
6% of dogs in stage B2 and 19% of dogs in stage C.  
A newer parameter to diagnose ID is RET-He. This marker has been suggested as reliable 
reflecting iron availability for Hb synthesis (Fuchs et al., 2017). In the present study, RET-He 
was similar in all groups. This parameter might only be decreased when iron deficiency 
becomes severe enough to affect hematopoiesis.  
Factors implicated in ID in people with CHF are ischemic insults initiating inflammatory 
processes (Dick and Epelman, 2016). Whilst ischemic injury plays a minor role in canine 
MMVD, inflammatory processes do occur in advanced CHF (Domanjko et al., 2018). 
Similarly, in our study, CRP was higher in dogs in stage C and negatively correlated with 
serum iron concentration. Further factors implicated in ID in humans are inadequate 
nutrition, micro-bleeding, gastritis and ulcers due to concomitant medication, low-protein diet 
and proteinuria because of additional renal disease, malabsorption because of intestinal 
mucosal edema and impaired gastrointestinal blood circulation (Sica, 2003; Okonko and 
Anker, 2004; Ather et al., 2012; McDonagh and Macdougall, 2015). In dogs, weight loss as a 
visible result of malnutrition has most recently been described as a typical sign of reaching 
the end stage in MMVD (Boswood et al., 2020). Likewise, in this study, the body condition 
score was significantly lower in dogs in stage C and negatively correlated with serum iron. 
 
Study limitations   
The CRP was higher in dogs with advanced heart failure and negatively correlated with 
serum iron concentration. Even though inflammation is known to be present in CHF in 
humans as well as in dogs, and inflammation is one postulated cause of ID in human CHF, 
inflammation is also known to affect iron metabolism, which might be a confounding factor. 
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Bone marrow iron staining, the gold standard for assessing iron stores (Burns et al., 1990; 
Grote Beverborg, 2018), was not performed due to its invasiveness. However, in view of the 
fact that any disease other than MMVD was an exclusion criterion, and comparing our data to 
recent human data suggests that ID was, indeed, present in these dogs (Grote Beverborg et 
al., 2018). With this perception, inflammation associated with CHF seems more likely to be 
causative both for higher CRP concentrations and ID, rather than inflammation causing only 
iron sequestration.  
Cardiac patients and normal dogs were prospectively enrolled irrespective of sex, age and 
body weight, i.e. they were not matched for these parameters. However, hematological and 
iron parameters should not be affected by age in adult dogs within the ranges used, and did 
not correlate in this study. 
 
Conclusions 
This study suggests ID to be a potential comorbidity in dogs with advanced MMVD. Further 
studies are necessary to prove the development of ID in the course of this disease, and, if 
present, if iron supplementation will have similarly positive effects on life span and quality, 
as in humans. 
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Table 1  
Demographic and selective echo data (mean + SD) in 30 healthy dogs and 70 dogs at 




§one-way ANOVA, except Chi Square test for sex; BCS, body condition score; LVDDN,  
left ventricular diameter in diastole normalized to body weight; LA/Ao, left atrial to aortic 
root ratio; na, not applicable. 
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Table 2  
Selective laboratory parameters (mean + SD) in 30 healthy dogs and 70 dogs at different 
stages of myxomatous mitral valve disease. 
 
Variable Unit Control 
N = 30 
Stage B2 
N = 33 
Stage C 





Hct % 48.2 + 4.7 45.2 + 7.4 46.4 + 5.6 42-55 0.15 
Hb g/dl 16.8 + 1.6 15.5 + 2.7 16.0 + 2.1 14.4-19.1 0.07 
RET-He pg 27.4 + 1.7 27.1 + 1.4 26.7 + 1.9 26-30 0.38 
MCH pg 23.2 + 1.1 23.3 + 1.1 23.1 + 1.1 23-26 0.75 
MCV fl 66.6 + 4.6 67.9 + 4.2 67.5 + 4.7 64-73  0.51 
MCHC g/dl 35.2 + 1.2 34.4 + 1.7 34.2 + 1.9 34-36 0.05 
Tc 103/ul 302 + 118 400 + 140 374 + 192 130-394 0.04 
CRP mg/l 3 + 9 4 + 11 27 + 49 <10 <0.01* 
 
Hct, hematocrit; Hb, hemoglobin; RET-He, reticulocyte hemoglobin equivalent; Tc, platelets; 
CRP, C-reactive protein. 
* Tukey’s range test: stage C versus control, P <0.01; stage C versus B2, P <0.01 
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Table 3  
Parameters of iron metabolism (mean + SD) in 30 healthy dogs and 70 dogs at different 
stages of myxomatous mitral valve disease. 
 












Ferritin ng/ml 159 + 59 174 + 73 198 + 188 60-190 0.46 Na 
 
Iron  ug/dl 156 + 45 151 + 57 118 + 56 50-230 0.007 0.016b 
0.030xyc 
Tsat  % 39 + 12 37 + 14 30 + 12 30-68 0.026 0.031b 
0.078c 
TIBC  ug/dl 414 + 82 410 + 79 392 + 98 240-440 0.306 Na 
 
 
Iron, serum iron concentration; Tsat, Transferrin saturation; TIBC, total iron binding 
capacity; na, not applicable. 
acontrol versus stage B2, bcontrol versus stage C, cstage B2 versus stage C.  
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Table 4 
Selective correlations in 100 dogs, 30 control dogs and 70 dogs with degenerative mitral 
valve disease at ACVIM stage B2 and C. 
 
*for abbreviations see tables 1, 2, 3  
 




Fig. 1: Serum iron concentration in control dogs and dogs with degenerative mitral valve 
disease at ACVIM stage B2 and C. The serum iron is significantly lower in stage C dogs 
compared to the other two groups. 
 
Fig. 2: Transferrin saturation (Tsat) in control dogs and dogs with degenerative mitral valve 
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